23andMe Holding Co. (ME)
|Net Income (ttm)||-335.95M|
|Day's Range||0.871 - 0.937|
|52-Week Range||0.610 - 3.480|
|Price Target||4.92 (+464.8%)|
|Earnings Date||Nov 8, 2023|
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliat... [Read more]
In 2022, ME's revenue was $299.49 million, an increase of 10.15% compared to the previous year's $271.89 million. Losses were -$311.66 million, 43.3% more than in 2021.Financial Statements
According to 3 analysts, the average rating for ME stock is "Strong Buy." The 12-month stock price forecast is $4.92, which is an increase of 464.80% from the latest price.
PRIVACY ALERT: Genetic Testing Company 23andMe Faces Class Action Investigation for Cyberattack Potentially Impacting Five Million Customers
23andMe Customers Are Urged to Contact Schubert Jonckheer & Kolbe LLP to Discuss Their Legal Rights SAN FRANCISCO , Nov. 13, 2023 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP today launched an inves...
Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin Announced launch of new 23andMe+ Total He...
DNA testing and genealogy companies are stepping up user account security by mandating the use of two-factor authentication, following the theft of millions of user records from DNA genetic testing gi...
The Company's first-of-its-kind health membership combines exome sequencing, blood testing and direct access to clinicians trained in genetics for ongoing disease prevention and early detection The Co...
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced data from its ongoing first...
23andMe Holding Co. ME, +0.39% said Tuesday it's launching a health action plan that will offer its clients personalized recommendations based on genetic and other health data. The South San Francisco...
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
23andMe+ members will receive customized action plans, from recommended lifestyle changes to clinician-ordered lab tests through 23andMe 23andMe+ members will receive customized action plans, from rec...
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe ...
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, ...
Since news of the hack, many customers have expressed worries their ethnicity and other sensitive information could be used against them if leaked.
Genetics testing company 23andMe on Tuesday sent emails to several customers to inform them of a breach into the "DNA Relatives" feature that allowed them to compare ancestry information with users wo...
The top Republican on the U.S. Senate's health committee has called on the chief executive of 23andMe to provide the panel with details after data from the family genetics website was advertised for s...
The same hacker who leaked a trove of user data stolen from the genetic testing company 23andMe two weeks ago has now leaked millions of new user records.
23andMe said that the profile information of some customers was accessed without their permission by a third party.
Genetic testing company 23andMe has been investigating a security incident after hackers advertised a trove of alleged stolen user data on a hacking forum last week. But the alleged stolen data may ha...
Federal law enforcement is now involved and third-party forensic experts are helping with the investigation, according to the company.
Days after user personal surfaced online, the genetic testing company 23andMe said it's requiring all users to reset their passwords “out of caution.” On Friday, 23andMe confirmed that hackers had obt...
23andMe user data leaked on dark web
Okta CEO Todd McKinnon reacts to the data leakage of 23andMe users on 'The Claman Countdown.'
User data from 23andMe accounts has been leaked and put up for sale on a dark web forum. Hackers likely gathered the data with leaked customer credentials for other platforms and services.
The company, which has launched an investigation into the attack, said Friday it could not yet confirm whether the leaked information is real.
A hacker is advertising millions of "pieces of data" stolen from the family genetics websites 23andMe, according to posts made to an online forum where digital thieves often advertise leaked data.
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer's (SITC) 2023 Annual Meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies 23andMe to present data on efficacy ...
23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell disea...
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
23andMe receives FDA approval to test for cancer variants
Yahoo Finance Live anchors Rachelle Akuffi and Brad Smith report on 23andMe's stock rising after the company received FDA approval to test for cancer variants.